165 related articles for article (PubMed ID: 38284223)
1. Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):509-519. PubMed ID: 38284223
[TBL] [Abstract][Full Text] [Related]
2. Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.
Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):237-250. PubMed ID: 38175140
[TBL] [Abstract][Full Text] [Related]
3. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
[TBL] [Abstract][Full Text] [Related]
4. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
5. Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review.
Vulto AG; Vanderpuye-Orgle J; van der Graaff M; Simoens SRA; Dagna L; Macaulay R; Majeed B; Lemay J; Hippenmeyer J; Gonzalez-McQuire S
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33213079
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars in Belgium: a proposal for a more competitive market.
Moorkens E; Vulto AG; Huys I
Acta Clin Belg; 2021 Dec; 76(6):441-452. PubMed ID: 32400319
[TBL] [Abstract][Full Text] [Related]
7. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market.
Río-Álvarez I; Cruz-Martos E
Expert Opin Biol Ther; 2024 Jun; ():1-15. PubMed ID: 38842367
[TBL] [Abstract][Full Text] [Related]
8. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
9. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?
Mehr SR; Brook RA
Pharmaceut Med; 2019 Feb; 33(1):1-8. PubMed ID: 31933270
[TBL] [Abstract][Full Text] [Related]
11. A health economic guide to market access of biosimilars.
Simoens S; Vulto AG
Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
[No Abstract] [Full Text] [Related]
12. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
13. A place for biosimilars in the changing multiple sclerosis treatment landscape.
Greenberg B; Giovannoni G
Mult Scler Relat Disord; 2023 Sep; 77():104841. PubMed ID: 37467536
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of biosimilar uptake in emerging markets.
Chhabra H; Mouslim MC; Kashiramka S; Rathore AS
Expert Opin Biol Ther; 2022 Jun; 22(6):679-688. PubMed ID: 35535988
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration.
Manolis CH; Rajasenan K; Harwin W; McClelland S; Lopes M; Farnum C
J Manag Care Spec Pharm; 2016 Sep; 22(9 Suppl):S3-9. PubMed ID: 27579939
[TBL] [Abstract][Full Text] [Related]
16. Market diffusion of biosimilars in off-patent biologic drug markets across Europe.
Böhm AK; Steiner IM; Stargardt T
Health Policy; 2023 Jun; 132():104818. PubMed ID: 37086662
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars in Oncology in the United States: A Review.
Nabhan C; Parsad S; Mato AR; Feinberg BA
JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
[TBL] [Abstract][Full Text] [Related]
18. The landscape of biosimilars in Saudi Arabia: preparing for the next decade.
Almutairi AR; Al-Samil AM; Alsayyari A; Yousef CC; Khan MA; Alhamdan HS; Al-Jedai A
Expert Opin Biol Ther; 2023; 23(8):679-688. PubMed ID: 37503858
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: A Value Proposition.
de Mora F
BioDrugs; 2019 Aug; 33(4):353-356. PubMed ID: 31175631
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]